Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

ShareIn commemoration of the 2024 World Diabetes Day, Merck Foundation, the philanthropic arm of Merck KGaA Germany, has ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s trading day neared its end, after the company announced its ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...